A Multi Center Breast FNAC Whole-Slide Cytology Dataset for AI-Assisted Patch-Wise Classification Using C1 to C5 Reporting Categories

A New Benchmark for AI in Cytopathology

The release of a multicenter breast fine needle aspiration cytology (FNAC) dataset, detailed in arXiv:2606.30209, represents a significant step forward for AI-assisted pathology. The dataset comprises 321 patients and 470 whole-slide images (WSIs), annotated using the standardized C1 to C5 reporting categories—a framework that maps directly to clinical decision-making, from non-diagnostic (C1) through malignant (C5). This is not merely another image collection; it is a purpose-built resource for patch-wise classification, a granular approach that trains models to analyze small regions of a slide rather than the entire image at once.

Why This Matters

The dataset’s multicenter origin is its strongest asset. Single-center datasets often encode site-specific biases—differences in staining protocols, scanner models, or patient demographics—that cause models to fail in real-world deployment. By pooling data from multiple institutions, this collection offers a more robust foundation for generalization. Additionally, the use of C1–C5 categories aligns with the Bethesda-like reporting system already used in cytology, meaning AI outputs could integrate directly into existing clinical workflows without requiring pathologists to learn a new taxonomy.

For AI practitioners, the patch-wise labeling strategy is particularly noteworthy. Whole-slide images are massive—often exceeding 100,000 pixels per dimension—making end-to-end classification computationally prohibitive and clinically opaque. Patch-wise classification allows models to identify diagnostically relevant regions (e.g., clusters of malignant cells) while ignoring stroma or debris. This mirrors how pathologists actually work: scanning at low power, then zooming in on suspicious areas. A model trained on this dataset could eventually serve as a triage tool, flagging high-risk patches for human review.

Implications for AI Practitioners

First, this dataset lowers the barrier to entry for researchers working on cytopathology AI. Previously, assembling a multicenter, clinically annotated FNAC dataset required years of institutional agreements and manual labeling. Now, teams can focus on model architecture and training strategies rather than data acquisition.

Second, the patch-wise approach introduces a specific technical challenge: how to aggregate patch-level predictions into a slide-level diagnosis. Simple majority voting may fail because malignant cells can be sparse. Practitioners will need to explore attention mechanisms, multiple instance learning, or uncertainty-aware aggregation to produce clinically reliable outputs.

Third, the C1–C5 scheme includes ambiguous categories (e.g., C3: atypical, probably benign; C4: suspicious, probably malignant). These are the hardest for AI to learn because they represent gray zones even for human experts. Models that perform well on this dataset will need to handle uncertainty gracefully—perhaps by outputting confidence intervals or flagging cases for second review rather than forcing a binary benign/malignant decision.

Finally, the dataset’s size (470 WSIs from 321 patients) is modest by deep learning standards. While sufficient for proof-of-concept studies, practitioners should expect that models trained on this data alone may not generalize to populations with different cancer prevalence or preparation techniques. Transfer learning from larger histopathology datasets (e.g., TCGA) will likely be necessary.

Key Takeaways

• The multicenter FNAC dataset with C1–C5 annotations provides a standardized, clinically aligned benchmark for training patch-wise classification models in cytopathology.
• Patch-wise labeling enables granular analysis that mirrors pathologist workflows, but requires sophisticated aggregation methods to produce slide-level diagnoses.
• The inclusion of ambiguous C3/C4 categories forces models to handle diagnostic uncertainty, a critical capability for real-world clinical deployment.
• At 470 WSIs, the dataset is a valuable starting point but will likely require augmentation via transfer learning from larger histopathology repositories.